An Egr-1-specific DNAzyme regulates Egr-1 and proliferating cell nuclear antigen expression in rat vascular smooth muscle cells

Zhang,Junbiao; Guo,Changlei; Wang,Ran; Huang,Luli; Liang,Wanqian; Liu,Runnan; Sun,Bing

doi:10.3892/etm.2013.1013

May 2013 Volume 5 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May 2013 Volume 5 Issue 5

Full Size Image

Article

An Egr-1-specific DNAzyme regulates Egr-1 and proliferating cell nuclear antigen expression in rat vascular smooth muscle cells

Authors:
- Junbiao Zhang
- Changlei Guo
- Ran Wang
- Luli Huang
- Wanqian Liang
- Runnan Liu
- Bing Sun
View Affiliations / Copyright

Affiliations: Department of Cardiovascular Internal Medicine, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Cardiovascular Internal Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Tuberculosis, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Pages: 1371-1374
|
Published online on: March 15, 2013

https://doi.org/10.3892/etm.2013.1013
Expand metrics +

Abstract

The aim of the present study was to transfect rat aortic smooth muscle cells with an early growth response factor‑1 (Egr‑1)-specific DNAzyme (ED5), to observe its effect on Egr-1 and proliferating cell nuclear antigen (PCNA) expression and to elucidate the mechanism of ED5-mediated inhibition of vascular smooth muscle cell (VSMC) proliferation. VSMCs in primary culture obtained by tissue block adhesion were identified by morphological observation and α smooth muscle actin (α-SM-actin) immunocytochemistry. The cells were then transfected with ED5 or scrambled ED5 (ED5SCR). The three groups of cells used in the present study were the control group, ED5 group and ED5SCR group. The expression levels of Egr-1 and PCNA protein were detected following transfection by analyzing and calculating the integral optical density value in each group. Primary culture of VSMCs and transfection of ED5 and ED5SCR were successfully accomplished. Following stimulation with 10% fetal calf serum, the Egr-1 protein was expressed most strongly at 1 h and demonstrated a declining trend over time; the expression of PCNA protein began at 4 h, peaked at 24 h and then demonstrated a slightly declining trend over time. Compared with the control group and the ED5SCR group, ED5 inhibited the expression of Egr-1 and PCNA (P<0.05). ED5 was able to inhibit the expression of Egr-1 and PCNA proteins in VSMCs to a certain extent and VSMC proliferation in vitro. DNAzyme gene therapy may be useful as a new method for treating vascular proliferative diseases, including atherosclerosis and restenosis.

View Figures

View References

1.	Clever YP, Cremers B, Krauss B, et al: Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention. 7(Suppl K): K32–K42. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Nakatani M, Takeyama Y, Shibata M, et al: Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol. 12:40–48. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Yamamoto H, Watanabe T, Miyazaki A, et al: High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia. J Am Geriatr Soc. 53:583–589. 2005.
4.	Rhachigian LM: Early growth response-1 in cardiovascular pathobiology. Circ Res. 98:186–191. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Carmi N and Breaker RR: Characterization of a DNA-cleaving deoxyribozyme. Bioorg Med Chem. 9:2589–2600. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Martin MM, Victor X, Zhao X, McDougall JK and Elton TS: Identification and characterization of functional angiotensin II type 1 receptors on immortalized human fetal aortic vascular smooth muscle cells. Mol Cell Endocrinol. 183:81–91. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Cutlip DE, Leon MB, Ho KK, et al: Acute and nine-month clinical outcomes after ‘suboptimal’ coronary stenting: results from the Stent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol. 34:698–706. 1999.
8.	Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med. 346:1773–1780. 2002. View Article : Google Scholar
9.	Holmes DR Jr, Leon MB, Moses JW, et al: Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 109:634–640. 2004.PubMed/NCBI
10.	Casterella PJ and Teirstein PS: Prevention of coronary restenosis. Cardiol Rev. 7:219–231. 1999. View Article : Google Scholar
11.	Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE and Baim DS: Mechanisms of restenosis and redilatation within coronary stents: quantitative angiographic assessment. J Am Coll Cardiol. 21:1166–1174. 1993. View Article : Google Scholar : PubMed/NCBI
12.	Ohtani K, Egashira K, Usui M, et al: Inhibition of neointimal hyperplasia after balloon injury by cis-element ‘decoy’ of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther. 11:126–132. 2004.
13.	Santiago FS, Atkins DG and Khachigian LM: Vascular smooth muscle proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. Am J Pathol. 155:897–905. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Teng YX, Liu GN and Zhou J: Effect of DNAzyme targeting early growth response factor-1 on endothelial function of injured artery in rats. Journal of China Medical University. 34:511–512. 2005.
15.	Han W and Liu GN: EGR-1 decoy ODNs inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of balloon-injured arteries in rat. Life Sci. 86:234–243. 2010. View Article : Google Scholar : PubMed/NCBI
16.	McArthur JG, Qian H, Citron D, et al: p27–p16 Chimera: a superior antiproliferative for the prevention of neointimal hyperplasia. Mol Therapy. 3:8–13. 2001.
17.	Miniati DN, Hoyt EG, Feeley BT, Poston RS and Robbins RC: Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen and Cdc2 kinase inhibit graft coronary artery disease. Circulation. 102:237–242. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Braun-Dullaeus RC, Mann MJ and Dzau VJ: Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:82–89. 1998. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

An Egr-1-specific DNAzyme regulates Egr-1 and proliferating cell nuclear antigen expression in rat vascular smooth muscle cells

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles